Voluntary announcement entering into strategic cooperation with xtalpi
Filed with HKEX · Stock code 3378 · · 3 pages · English
Summary by 6ix AI
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced a strategic cooperation with Shenzhen XtalPi Technology Co., Ltd. to explore the application of AI in drug research and development. The cooperation aims to enhance R&D efficiency and success rates while optimizing biologics screening and molecule optimization processes. The specific terms of the cooperation will be determined through subsequent agreements based on actual needs. This announcement is made voluntarily by the company's board of directors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. on 6ix
Earlier from Hanx Biopharmaceuticals (Wuhan)
- 2026 Interim report
- Proposed placing of unlisted warrants under Specific mandate
- Next Day Disclosure Return
- Voluntary announcement notice on voluntary extension of lock-up period by shareholders
- Voluntary announcement inclusion of Hanx Biopharmaceuticals in the FTSE global micro cap index
Later from Hanx Biopharmaceuticals (Wuhan)
All Hanx Biopharmaceuticals (Wuhan) news releasesFollow Hanx Biopharmaceuticals (Wuhan) into a list and get an email when it puts out news.
Follow Hanx Biopharmaceuticals (Wuhan)